Participants must discontinue use of the following agents within  days prior to therapy\r\n* Strong CYPA inhibitors that treat HIV\r\n* Other strong CYPA inhibitors\r\n* Moderate CYPA inhibitors should be used with caution but are not excluded; if  moderate CYPA inhibitors are used concurrently, one must be discontinued at least  days ( week) prior to the initiation of chemotherapy\r\n* P-glycoprotein inhibitors\r\n* If patients are taking any of these excluded medications, they must be discontinued at least  days ( week) prior to the initiation of chemotherapy\r\nAll concomitant medications must be reviewed by the study chair or co-chair prior to enrollment by email; because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of
Patients who have received drugs that are strong inducers of CYPA within  days prior to study enrollment are not eligible; while on study, concomitant use of strong CYPA inhibitors, BCRP inhibitors (cyclosporine, eltrombopag, gefitinib), and UGTA inhibitors, (diclofenac, ketoconazole, probenecid, silibinin, nilotinib and atazanavir) should be avoided
Exposure to potent or moderate inhibitors or inducers of CYPA/ and CYPC if taken within the stated washout periods before the first dose
Concurrent use of potent CYPA inhibitors, such as ketoconazole and erythromycin, should be avoided during the study treatment with T-DM
Subjects must not be receiving potent CYPA inducers or inhibitors
Co-administration with strong inhibitors of CYPA (e.g., ketoconazole, itraconazole, ritonavir) or P-glycoprotein (PgP) is prohibited; co-administration with moderate CYPA inhibitors (e.g., erythromycin, fluconazole) or PgP inhibitors may be used with caution and everolimus dosing must be discussed with principle investigator (PI) at the time of enrollment
Patients currently receiving and unable to stop using medications known to be potent inhibitors or inducers of CYPA
Participant has received the following within  days prior to the first dose of study drug: corticosteroid therapy, CYPA inhibitors, CYPA inducers.
Patients currently receiving and unable to stop using medications known to be potent inhibitors or inducers of CYPA
Concurrent use of potent CYPA inhibitors, such as ketoconazole and erythromycin, should be avoided during the study treatment with nab-paclitaxel
Use of potent inhibitors or inducers of cytochrome P enzymes CYPA within  days prior to first study drug administration.
Subject takes cytochrome P, family , subfamily A (CYPA) inhibitors within  days or inducers within  days prior to the study drug administration; any questions or clarifications of these determinations should be brought to the attention of the principal investigator (PI); the PI will make the final determination on when it is safe to initiate ABT- (ilorasertib) therapy under circumstances where the magnitude or relevance of possible CYPA inhibitors/inducers is unclear in the protocol appendix
Cobimetinib is metabolized by the hepatic cytochrome PA (CYPA) enzyme. Drugs CYPA/ inhibitors and inducers should be avoided Atezolizumab-Specific Exclusion Criteria (Cohorts II and III Only)
Concurrent use of selective serotonin reuptake inhibitors or aromatase inhibitors
Concomitant use of CYPA inhibitors
Concomitant therapy with potent inhibitors of CYP A (e.g. ketoconazole, verapamil etc) or with potent CYP A inhibitors (fluoroquinolone antibiotics including ciprofloxacin, levofloxacin, and norfloxacin; ticlopidine, cimetidine, amiodarone, etc.)
Concomitant use of potent CYPA/ inhibitors during the treatment phase of the study and within  hours prior to starting study drug administration.
Concomitant use of potent CYPA/ inhibitors during the treatment phase of the study and within  hours prior to starting study drug administration
Cabozantinib is metabolized by CYPA; the metabolism and consequently overall pharmacokinetics of cabozantinib could be altered by inhibitors and/or inducers or other substrates of CYPA; it is recommended that chronic concomitant treatment with strong CYPA inhibitors (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. Johns wort) or inducers should be avoided; if patients are taking any strong CYPA inhibitors, alternate medications with no or minimal CYPA inhibitors should be sought prior to trial enrolment; while mild inhibitors/inducers of these cytochrome P isoenzymes are not specifically excluded, investigators should be aware that cabozantinib exposure may be altered by the concomitant administration of these drugs, and avoidance is also recommended
Concomitant use of CYPA inhibitors
Medical need for the continued use of potent inhibitors/inducers of CYPA
Concomitant use of CYPA inhibitors
Concomitant use of cytochrome P (CYPA) inhibitors or inducers is allowed but should be monitored closely for the use of strong inhibitors and/or inducers; patient is strongly advised to avoid grapefruit or grapefruit juice and herbal supplements with high risk of interaction with CYPA or CYPC, such as St. Johns Wort while on study
Patients on proton pump inhibitors, potent CYPA or P-glycoprotein substrates, inhibitors or inducers a minimum  day period washout required unless discontinuation or substitution is not in the best interests of the patient as determined by the investigator; in instances where use of these agents is felt to be required for optimal management, inclusion of such patients should be discussed with the principal investigator (PI) and the rationale documented; these patients, if enrolled on study, may require dose modifications for both axitinib and bosutinib
Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be potent inhibitors of CYPA (at least  week prior) and potent inducers of CYPA (at least  week prior) will only be eligible at the principal investigator's (PIs) discretion
Current use of food or drugs known to be potent inhibitors or inducers of CYPA
Prior use of neutrophil elastase inhibitors
PHASE II: Concomitant use of known potent CYPA inhibitors
Subjects currently receiving (or unable to stop using prior to receiving the first dose of trial drug) medications or herbal supplements known to be potent inhibitors of cytochrome P (CYP)A or CYPC (must stop at least  week prior), potent inducers of CYPA or CYPC (must stop at least  weeks prior), or drugs mainly metabolized by CYPA with a narrow therapeutic index (must stop at least one day prior).
Subjects currently receiving (or unable to stop using prior to receiving the first dose of study drug) medications or herbal supplements known to be potent inhibitors of CYPA or CYPC must stop at least  week prior to taking MSCA. Subjects receiving potent inducers of CYPA or CYPC must stop at least  weeks prior to taking MSCA. Those receiving drugs mainly metabolized by CYPA with a narrow therapeutic index as judged by the Investigator (and after optional consultation with the Sponsor) must stop at least one day prior to taking MSCA.
Current use of food or drugs known to be potent CYPA inhibitors, drugs known to be potent CYPA inducers, and drugs that are known to prolong the QT interval
On medications which are CYPA inhibitors.
No concomitant medications such as phenytoin, carbamazepine, rifampicin, barbiturates, ketoconazole and itraconazole, which are potent inducers of CYPA or potent inhibitors of CYPA
Subjects who are currently receiving prescription or non prescription medications or other products known to be moderate or potent inhibitors/inducers of CYPA, P-gp, or CYPC.
Bcl inhibitors
Current use of food or drugs known to be potent CYPA inhibitors, drugs known to be potent CYPA inducers, and drugs that are known to prolong the QT interval.
Concomitant administration with strong inhibitors or inducers of CYPA should be avoided; it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of
Current use of a prohibited medication or planned use of any forbidden medications during treatment with GSK and abiraterone/enzalutamide. This includes medications with significant risk of Torsades de pointes as well as those that are potent inducers or inhibitors of CYPA enzymes or strong inhibitors of CYPC.
Patients receiving any medications or substances that are potent inhibitors or inducers of CYPA are ineligible; the required washout period for strong inhibitors is  weeks and at least one week for moderate inhibitors; the required washout period prior to starting olaparib is  weeks for enzalutamide or phenobarbital and  weeks for other agents
Concomitant use of potent P A (CYPA) inducers
Patients receiving the following classes of inhibitors of cytochrome P A (CYPA):\r\n* Azole antifungals\r\n* Macrolide antibiotics\r\n* Protease inhibitors
Prior use of raf-kinase inhibitors, VEGF inhibitors, MEK inhibitors or farnesyl transferase inhibitors, with the exception of sorafenib
For Cohort A: Is currently receiving strong or moderate inhibitors of CYPA including azole antifungals; macrolide antibiotics; or protease inhibitors
For Cohort B: Is currently receiving any of the following classes of inhibitors of CYPA: azole antifungals; macrolide antibiotics; or protease inhibitors
Current use or anticipated inability to avoid potent CYPA/ inhibitors or inducers (please refer to the Inlyta [axitinib] prescribing information) during participation in the study.
Concomitant administration with strong inhibitors or inducers of CYPA should be avoided; it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or minimize use of
Use of estrogens or -? reductase inhibitors or AR inhibitors.
Use caution when co-administered with moderate CYPA/PgP inhibitors (e.g., amprenavir, fosamprenavir, aprepitant, erythromycin, fluconazole, verapamil, diltiazem).
Use of potent CYPA inhibitors or inducers
Exposure to potent or moderate inhibitors or inducers of CYPA/, Pgp (MDR) and BCRP if taken within the stated washout periods before the first dose of study treatment
-? reductase inhibitors
Received potent cytochrome P A (CYPA) inhibitors (such as fluconazole, ketoconazole, and clarithromycin) within  days prior to the first dose of study treatment
Patients on immunosuppressive agents (e.g., TNF pathway inhibitors, phosphoinositide  [PI] kinase inhibitors) within  days of study treatment
Patients who have experienced intolerable adverse events per treating investigator due to other PARP inhibitors, mTOR inhibitors, PI kinase inhibitors, or AKT inhibitors
Concomitant use of significant CYPA inhibitors unless able to be switched to a non-CYPA inhibiting medication without risk of worsening underlying condition and able to meet all other inclusion criteria
Potent inhibitors of cytochrome P A (CYPA)
Use of oral anticoagulants. Use of subcutaneous anti coagulation is allowed. Concurrent use of potent or moderate inhibitors or inducers of CYPA and/or CYPC.
Current (including their administration within  days prior to study entry) use or anticipated need for food or drugs that are strong CYPA inhibitors.
Prior treatment with a gamma secretase inhibitors or other Notch signaling inhibitors.
Cytochrome P CYPA inducers and inhibitors within  weeks prior to day 
Phase II only: Prior treatment with RAF inhibitors, Wnt pathway inhibitors, cetuximab, panitumumab, and/or other EGFR inhibitors
Patients taking CYPA inducers or inhibitors are not eligible since it is not known whether the study drug is metabolized through this pathway. The following CYPA inhibitors/inducers are not permitted during the trial - the azole antifungal - fluconazole, erythromycin, phenobarbital, verapamil.
Major surgery within  weeks prior to study day  Active infection Anti-coagulation therapy Concomitant treatment with potent CYPA inducers
Administration of cytochrome P CYPA inducers and inhibitors within  weeks before day  and during the study
Treatment with CYPA inducers within  days before the first dose of MLN. Treatment with CYPA inhibitors within  days before the first dose of MLN; however, voriconazole and fluconazole need only be stopped for  days before MLN. Patients must have no history of amiodarone use in the  months before the first dose of MLN
Current or recent (within -months) use of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine or strong CYPA inhibitors (i.e. clarithromycin, HIV protease inhibitors, and itraconazole)
Patients should not be taking concomitant medication that are cytochrome P A (CYPA) inducers or potent inhibitors (+++) and should try to avoid taking proton pump inhibitors and histamine (H) antagonists during rest of treatment period; the above medications will be continued only if medically necessary and their use will be noted
Concomitant use of CYPA inhibitors or inducers;
Require treatment with any known inducers and inhibitors of isoenzyme CYPA
Patient currently using, or has previously used CYPA inducers or inhibitors within  to  days prior to the initiation of oral therapy.
Concomitant use of CYPA inhibitors
Use of chronic prescribed medications which are potent inducers or inhibitors of CYPA
DONOR: Concurrent treatment with strong inhibitors of hepatic CYP A (i.e. clarithromycin, erythromycin, protease inhibitors, azole antifungals)
Current use of: Finasteroid (propecia), Efavirenz, Red Clover, Ketoconazole, CYPA Inhibitors
Exposure to strong inhibitors or inducers of CYPA/, P-glycoprotein (Pgp) (MDR) and BCRP if taken within the stated washout periods before the first dose of study treatment; treatment with moderate inhibitors or inducers of CYPA/, Pgp (MDR) and BCRP should be used only if necessary and when alternatives are unavailable; cases should be discussed with the principal investigator